WO2017090902A1 - Film buccal hémostatique et de protection des plaies - Google Patents

Film buccal hémostatique et de protection des plaies Download PDF

Info

Publication number
WO2017090902A1
WO2017090902A1 PCT/KR2016/012271 KR2016012271W WO2017090902A1 WO 2017090902 A1 WO2017090902 A1 WO 2017090902A1 KR 2016012271 W KR2016012271 W KR 2016012271W WO 2017090902 A1 WO2017090902 A1 WO 2017090902A1
Authority
WO
WIPO (PCT)
Prior art keywords
oral
adhesive layer
film
weight
parts
Prior art date
Application number
PCT/KR2016/012271
Other languages
English (en)
Korean (ko)
Inventor
윤세영
Original Assignee
티비엠 주식회사
주식회사 착한생각
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 티비엠 주식회사, 주식회사 착한생각 filed Critical 티비엠 주식회사
Priority to EP16868801.8A priority Critical patent/EP3381448A4/fr
Priority to JP2017533518A priority patent/JP6941839B2/ja
Priority to US15/322,063 priority patent/US10582915B2/en
Priority to CN201680004311.2A priority patent/CN107106512A/zh
Priority to CA3044944A priority patent/CA3044944C/fr
Priority claimed from KR1020160141695A external-priority patent/KR101901660B1/ko
Publication of WO2017090902A1 publication Critical patent/WO2017090902A1/fr
Priority to PH12017501527A priority patent/PH12017501527A1/en

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug

Definitions

  • the present invention relates to oral hemostasis and wound protection film, and more particularly, to oral hemostasis and wound protection film that can be attached to the wound site of the oral cavity to delay or prevent microbleeding and control the release of the active ingredient.
  • Drug delivery through the oral mucosa is very useful for drugs that are easily metabolized during oral administration, drugs with low bioavailability, and those with gastrointestinal disorders, which are easy to apply and remove, and are irritated or damaged compared to other mucosa. Because it is less sensitive to, it is attracting attention as a route of administration of new drugs. Therefore, not only simple oral disease treatment, but also various drugs capable of systemic delivery in a small amount can be applied to the oral mucosa.
  • the formulations applied to the oral mucosa mainly consist of liquids, troches, and ointments. However, these formulations do not have a constant single dose, and the applied drug is easily lost by saliva, and thus, a constant drug cannot be expected.
  • Korean Patent Laid-Open Publication No. 10-2005-0055898 discloses a technique of forming a protective film that prevents the penetration of saliva, such as saliva, on the surface of a drug formulation in a liquid or gel form to prevent the drug from being easily lost.
  • a protective film is formed on the surface of the gel, it is difficult to use for a long time, and there is a problem of preventing drug release depending on the type of polymer or the thickness of the layer.
  • oral mucoadhesive films have been developed to solve the problem of ointments or gel type preparations (eg RAPIDFILM, tesa Labtec GmbH).
  • these adherent films can exhibit a constant dose and efficacy, while in a short time (about 3 minutes) the film melts and releases all of the active ingredients locally orally or temporarily in the digestive tract. There was a problem.
  • Korean Patent Laid-Open Publication No. 10-2005-0119914 discloses a tooth- and gum-attachable sheet that can be attached for a long time, but the sheet is composed of four layers, which maintains a relatively large thickness. There was a problem in that there was a sense of foreign body, which not only lowered the patient's compliance, but also easily detached from the oral mucosa by swelling by saliva. In addition, it includes a water-insoluble adhesive layer, so that the patient has to detach the sheet attached to the oral cavity by hand, and the inconvenience of use along with the cleaning problem has been raised. Although there are inventions for fast-release preparations that are rapidly releasing in domestic and foreign markets, there are no mucoadhesive preparations that adhere to the oral cavity and release controlled drug substances. Indeed, products such as Listerin's Breath Strip, sold in the United States, are in the form of a film that melts in about 3 minutes in the oral cavity.
  • the present invention is to provide oral hemostasis and wound protection film that can be attached to the oral mucosa, which can absorb or emulsify the blood or abscess.
  • the present invention provides an oral hemostasis and wound protection film that can control the release of the drug substance while being attached for a long time in the oral cavity for 10 minutes or more.
  • the present invention provides a thin film oral hemostasis and wound protection film that does not easily separate in the oral cavity without the patient feeling foreign body.
  • the present invention provides an oral hemostasis and wound protection film which does not require the patient to detach the sheet attached to the oral cavity by hand.
  • An adhesive layer comprising any one or more of a surfactant, an oil and a plasticizer, a hydrophilic polymer, and a disintegrant, attached to a wound site to delay or prevent microbleeding;
  • a water-insoluble polymer comprising a support layer on the adhesive layer to protect the adhesive layer from the tongue, saliva or food in the oral cavity,
  • the disintegrant is related to oral hemostasis and wound protection film, characterized in that the dissolution is released upon reaction with blood to form microchannels in the adhesive layer.
  • the present invention may include polyols, alcohols, and biodegradable polymers in a partially swollen state to absorb and bleed local blood or abscesses.
  • the film of the present invention has a high elongation rate and thus maintains adhesion even when absorbing blood, saliva and abscess in the oral cavity.
  • the film of the present invention may include a disintegrant which dissolves and reacts with blood to form microchannels that become drug release pathways, thereby controlling the amount and size of the drug release.
  • FIG. 1 is a conceptual diagram of the oral hemostasis and wound protection film of the present invention.
  • the film includes an adhesive layer 10 and a support layer 20.
  • the adhesive layer 10 is attached to one surface is in direct contact with oral hard tissue or soft tissue, the support layer 20 is formed on the other surface of the adhesive layer 10 so that the adhesive layer is not easily dissolved by tongue or saliva. do.
  • the adhesive layer 10 includes at least one of a surfactant, an oil and a plasticizer, and a hydrophilic polymer and a disintegrant.
  • the adhesive layer may further include a drug.
  • the hydrophilic polymer functions as a base material of the adhesive layer, and the hydrophilic polymer uses a polymer that generates adhesion when hydrated.
  • the hydrophilic polymer is a cellulose-based polymer of carboxymethyl cellulose, carboxypropyl cellulose or a salt thereof, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, hydroxypropyl ethyl cellulose, gum
  • the series of polymers are gelangum, xanthan gum, guar gum, carrageenan gum, Karayan gum, arabic gum and alginate gum.
  • synthetic polymers such as polyvinyl alcohol, poloxamer, polyvinylpyrrolidone, polyvinylpyrrolidone-vinylacetate copolymer, polyacrylic acid, carbopol, polyquater Nium-11, 39 (polyquaternium-11, 39), polyalkylvinylether-maleic acid copolymer (PVM / MA copolymer: Gantgrez AN 119, 139, S-97), and polyox Gin may be used alone or in combination of two or more selected from the group.
  • synthetic polymers such as polyvinyl alcohol, poloxamer, polyvinylpyrrolidone, polyvinylpyrrolidone-vinylacetate copolymer, polyacrylic acid, carbopol, polyquater Nium-11, 39 (polyquaternium-11, 39), polyalkylvinylether-maleic acid copolymer (PVM / MA copolymer: Gantgrez AN 119, 139, S-97), and
  • the adhesive layer includes any one or more of a surfactant, an oil, and a plasticizer.
  • the said surfactant can hold
  • the surfactant may be a variety of surfactants, including pharmaceutically acceptable anionic, cationic, nonionic or amphoteric surfactants.
  • the surfactant may be a polyoxyethylene glycolated natural or hydrogenated castor oil, an ester of mono or trilauryl, palmityl, stearyl or oleyl, polyoxyethylene stearic acid ester, polyoxyethylene-polyoxypropylene Copolymer, polyoxyethylene-polyoxypropylene block copolymer, sodium dioctylsulfosuccinate or sodium lauryl sulfosate, phospholipids, propylene glycol dicaprylate, propylene glycol dilaurate, propylene glycol isostearate, propylene glycol laurate Latex, propylene glycol ricinoleate or propylene glycol caprylic-capric acid diesters, trans-esterification reaction products of natural vegetable oil triglycerides with polyalkylene poly
  • the oil may be silicone oil, liquid paraffin, rosin wax solution, soybean oil, olive oil, sesame oil, castor oil, fat soluble vitamins, fat soluble vitamin acetate, and the like.
  • the oils can also serve as plasticizers.
  • the plasticizer used to impart flexibility and elasticity to the film may be selected from the group consisting of acetyl triethyl citrate, citrate ester, tricetin and triethyl citrate.
  • the disintegrant may be dissolved and released upon reaction with blood to form microchannels in the adhesive layer, and the drug may be released through the channel.
  • the amount of disintegrant By controlling the amount of disintegrant, the size and distribution of the channel can be controlled, thereby controlling the amount of drug released.
  • the disintegrant may be any one or more selected from polyols such as glycol, glycerin, sorbitol, and sebum, and xylitol lactose, magnesium stearate, crystalline cellulose, and crospovidone.
  • the drug includes all drugs suitable for absorption from the oral mucosa.
  • drugs that can be used in the present invention include oral disease agents such as anti-inflammatory agents and fungicides, antihistamines, tissue repair agents, hemostatic agents, hormones, antihypertensive agents, antibiotics, and bronchodilators.
  • anti-inflammatory agents examples include trinexamic acid, lysozyme chloride, sodium azulene sulfonate, dipotassium glycyrrhinate, ammonium glycyrrhinate, glycyrrhetinic acid, bromeloline, serapeptase, pranopropene, ibuprofenpiconol, furesterone, and root root Extract, epidahydrocholesterin, bupecsa film, upenamat, mylar tincture, shiho, fukyeong, yellow white, hydrocortisone acetate, predonisolone acetate, predonisolone, hydrocrtisone, triamcinolone acetonide, and the like.
  • disinfectant examples include potassium iodide, liquid phenol phenol, cetylpyridinium chloride, chlorohexidine gluconate, chlorhexidine hydrochloride, decualinium chloride, creosote, thymol, triclocarbam, benzalkonium chloride and benzyl chloride Tonium, acriol, oxydol, ethanol, isopropanol, mercurochrome, cresol, isopropylmethylphenol, phenyl salicylate, sulfadiazine, homosulfamine, cinnamon oil and the like.
  • antihistamines examples include chlorpheniramine maleic acid, diphenhydramine salicylic acid, diphenylpyralline hydrochloride, mequitazine hydrochloride, triprolidine hydrochloride, maleic acid carbinoxamine, diphenhydramine hydrochloride, diphenhydramine tannin acid, dimenhydrinate and hydrochloric acid.
  • Promethazine the prooxamic acid promethazine, meclizin hydrochloride, isopentyl hydrochloride, and the like.
  • tissue repair agents include sodium copper chlorophyllin, allantoin, aldioxa, methylmethioninesulfonium chloride, squavalate, asiaticoside, hydrochloric acid setlaxate, sofalcone, gefarnate, maleic acid tributhin, teflon and heparin-like. Substances, and the like.
  • Examples of local anesthetics include dibucaine hydrochloride, dibucaine, lidocaine hydrochloride, lidocaine, ethyl benzoate, oxetase, and ticaine.
  • Cinnamon oil cinnamon oil, myrrh tincture, sea tiger, Fuling, yellowish white, sperm component, dense tincture, latania tincture, soft-hopping, horse riding, gilyeong, safflower and the like.
  • Topical protective agents such as glycerin and concentrated glycerin
  • topical stimulants such as l-menthol, peppermint oil and dl-menthol
  • tissue astringents and disinfectants such as hinoki thiol
  • hemostatic agents such as carbazochrome, ascorbic acid and susu Vitamins such as calcium corbate, calcium tocopherol acetate and tocopherol zucchini, pantothenol, pyridoxine hydrochloride
  • blood circulation promoters such as benzyl nicotinate
  • blood circulation promoters such as sodium polyethylenesulfate
  • antibiotics such as minocycline hydrochloride.
  • the adhesive layer may include 0.1 to 60 parts by weight of the surfactant, oil or plasticizer and 0.1 to 30 parts by weight of the disintegrant, relative to 100 parts by weight of the hydrophilic polymer.
  • the adhesive layer may include 0.1 to 60 parts by weight of the surfactant or oil, preferably 1 to 40 parts by weight, and more preferably 1 to 30 parts by weight, based on 100 parts by weight of the hydrophilic polymer.
  • the adhesive layer may include 0.1 to 60 parts by weight, preferably 1 to 40 parts by weight, more preferably 1 to 20 parts by weight, and more preferably 1 to 15 parts by weight, based on 100 parts by weight of the hydrophilic polymer. have.
  • the disintegrant may be used 0.1 to 30 parts by weight, preferably 1 to 25 parts by weight, more preferably 1 to 20 parts by weight relative to 100 parts by weight of the hydrophilic polymer.
  • the adhesive layer may include 0.01 to 20 parts by weight of the drug relative to 100 parts by weight of the hydrophilic polymer.
  • the adhesive layer may be attached to the oral mucosa in a swollen state, including 0.1 to 30% by weight of water relative to the total weight of the adhesive layer.
  • a swollen state including 0.1 to 30% by weight of water relative to the total weight of the adhesive layer.
  • the swelling state is maintained for a long time, so that the absorption of blood or abscess can be performed more quickly.
  • partial swelling means that the pressure-sensitive adhesive layer is not fully swollen.
  • the adhesive layer may further include 0.1 to 30 parts by weight of a lipophilic softener relative to 100 parts by weight of the hydrophilic polymer.
  • the hydrophilic polymer and the drug forming the pressure-sensitive adhesive layer is dissolved by saliva and gradually lost.
  • the lipophilic softener since the lipophilic softener is not dissolved by saliva, the relative content in the pressure-sensitive adhesive layer increases over time.
  • the lipophilic softener with increased relative content in the adhesive layer gradually penetrates into the adjacent support layer to soften the support layer 20, and as a result, the support layer is lost by saliva.
  • the softener of the present invention serves to soften and lose the support layer, which is a water-insoluble layer, by moving the material from the pressure-sensitive adhesive layer 10 to the support layer 20 over time.
  • the drug delivery system of the present invention prevents the adhesive layer from rapidly decomposing due to the slow disappearance of the support layer, thereby enabling sustained release of the drug.
  • the drug release time and the content of the drug carrier (film) can be controlled according to the content of the softener and the thickness of the support layer.
  • the softener may be any one selected from triethyl citrate, dibutyl sebacate, acetyl triethyl citrate and triacetin.
  • the adhesive layer may be formed by dissolving the components in a solvent and then drying.
  • the solvent may be water, methanol, ethanol, acetone, isopropanol, ethyl acetate and the like, preferably water is used.
  • the adhesive layer may have a thickness of 50 to 1,500 ⁇ m, preferably 100 to 1200 ⁇ m, and most preferably 600 to 1,200 ⁇ m.
  • the support layer 20 may be prepared by mixing a water-insoluble polymer in a solvent.
  • the support layer is located on the adhesive layer serves to protect the adhesive layer from the tongue and food in the oral cavity.
  • the support layer 20 of the present invention may be softened and lost by the softening agent of the adhesive layer as described above.
  • the support layer 20 may have a thickness of 5 to 300 ⁇ m, preferably 10 to 150 ⁇ m, and most preferably 10 to 80 ⁇ m.
  • the water-insoluble polymer is polyvinylacetate, ethyl cellulose, polymethyl methacrylate, methacrylic acid copolymers, for example methacryloylethylbetaine / methacrylate copolymer (yukaformer), methacrylic copolymer, amino Alkylmethacrylate copolymers (Eudragit E, RL), cellulose acetate phthalate, shellac, polyethylene, PVC, polyurethane, polyethylene alone or mixtures thereof.
  • methacryloylethylbetaine / methacrylate copolymer for example methacryloylethylbetaine / methacrylate copolymer (yukaformer), methacrylic copolymer, amino Alkylmethacrylate copolymers (Eudragit E, RL), cellulose acetate phthalate, shellac, polyethylene, PVC, polyurethane, polyethylene alone or mixtures thereof.
  • the support layer may be used by dissolving a surfactant, a plasticizer, or an oil and a softener in a solvent.
  • a pressure-sensitive adhesive layer solution and a support layer solution using the components shown in Table 1 and Table 2.
  • a pressure-sensitive adhesive layer solution was applied on the release layer and then dried to prepare a pressure-sensitive adhesive layer film.
  • the support layer solution was applied onto the adhesion layer film and dried. The bilayer film thus prepared was cut to a predetermined size.
  • Comparative Example 2 uses Reso-Pac®, and Comparative Example 3 uses dental hygiene gauze.
  • hemostatic film Oral hemostasis and wound protection films (hereinafter, hemostatic film) prepared in Examples 1 to 3 and Comparative Example 1 were used as dissolution rate test samples.
  • the dissolution test method 2 (paddle method) of the Korean Pharmacopoeia general test method. Specifically, the eluate was eluted at 900 mL (pH 6.8 liquid), at a temperature of 37 ⁇ 0.5 ° C., and at a rotational speed of 50 rpm. The eluate was taken at 10 minute intervals from the beginning of the experiment and evaluated from 5 minutes to 1 hour. As the eluting material, blue # 1 dye was used, and the degree of release was divided into five stages and visually evaluated. The results are shown in Table 3.
  • Table 3 shows that Examples 1 to 3 release the pigment at a faster time than Comparative Example 1.
  • the pigment release time of Examples 2 and 3 containing more disintegrant was faster than that of Example 1. That is, Table 1 shows faster release with more disintegrants.
  • the rate of release can be controlled by adjusting the disintegrant.
  • the degree of wound healing was evaluated with the oral hemostasis and wound protection films (hereinafter hemostatic film) prepared in Examples 4 to 6 and Comparative Examples 2 and 4. Seventy-two male Sprague-Dawley rats (16 to 18 weeks old) were divided into three groups and stored in a standard breeding case. 5% isoflurane, ketamine hydrochloride, and xylaizne were used and local anesthesia was performed with lidocaine. Surgical defects were used for 5 mm trephine bur. The experimental group and the control group were applied to the wounded area by calvarial defect procedure, and the wound healing was compared 4 and 8 weeks after the closure.
  • hemostatic film the oral hemostasis and wound protection films prepared in Examples 4 to 6 and Comparative Examples 2 and 4. Seventy-two male Sprague-Dawley rats (16 to 18 weeks old) were divided into three groups and stored in a standard breeding case. 5% isoflurane, ketamine hydrochloride, and xylaizne
  • Example 3 was shown to be more effective by the action of the bactericidal component CPC compared to Example 4.
  • Examples 4 and 5 were similar in effect, but Example 5 was slightly more effective due to the high disintegrant and water content. With this ingredient, you can protect your dried skin first.
  • Reso-Pac® Comparative Example 2
  • Reso-Pac® Comparative Example 2
  • This formulation is less effective in protecting the wound because it disappears over time when applied to the wound.
  • Comparative Example 4 no surfactant was used. Because of this, it is difficult to protect the wound in close contact with the wounded areas where the bends and oily components remain, and the stimulation caused by the excessive use of alcohol may have produced a reverse synergistic effect.
  • hemostatic film Oral hemostasis and wound protection film (hereinafter hemostatic film) prepared in Examples 4 to 6 and Comparative Examples 1 to 3 to evaluate the degree of hemostatic prevention is shown in Table 5.
  • Absorption rate (ASTM D570) was applied as an evaluation method. Make the hemostatic film 10 ⁇ 10 (mm) in size and trap it in the mesh. Fill the spray bottle with saline solution (0.9% normal saline solution) and spray it 10 times on the hemostatic film in the mesh. Then, it is placed on a nonwoven fabric to remove excess moisture. And it compresses and compresses for 1 minute with a weight of about 10g to remove the surface moisture. The weight of the sample was obtained by subtracting the weight of the mesh and the absorbency was measured by the following equation. It was evaluated whether the absorption of blood or abscess can be reacted more rapidly according to the content of purified water inside the adhesive layer.
  • hemostatic film Oral hemostasis and wound protection film (hereinafter hemostatic film) prepared in Examples 5, 6 and Comparative Examples 2 to 4 evaluated the usability and are shown in Table 6. Usability was judged by satisfaction according to the degree of comfort when attached to the oral cavity. Evaluation was conducted for 30 people.
  • Examples 5 and 6 scored higher than Comparative Examples 2-4.
  • Example 6 which had a high score, it was determined to be due to the synergistic effect of the surfactant, the plasticizer, and the softener.
  • surfactants and plasticizers / oils can be used to some extent without the softener.
  • the function of the above components seems to provide a condition for the polymer surface of the preparation to bind well with the micro surface of the oral mucosa as the polymer of the preparation becomes flexible at the molecular level.
  • Comparative Example 2 had a large amount of foreign body in the form of ointment
  • Comparative Example 3 was the lowest satisfaction because it is possible to absorb the fluid due to the characteristics of the gauze, but low hemostasis.
  • Comparative Example 4 only the softener was used alone, and the usability effect was not high.
  • the present invention can be used as a film that can absorb and bleed local blood or abscesses.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)

Abstract

La présente invention concerne un film buccal hémostatique et de protection des plaies qui peut être appliqué sur une zone coupée au niveau de la cavité buccale de façon à retarder ou empêcher des micro-saignements et pour contrôler la libération d'agents thérapeutiques. La présente invention comprend un polyol, un alcool et un polymère biodégradable sous un état partiellement gonflé, permettant de ce fait d'absorber le sang ou le pus au niveau de la zone d'application, et d'arrêter le saignement. En outre, le film selon l'invention présentant un taux d'allongement élevé, il est possible de maintenir une force d'adhésion après l'absorption de sang, de salive et de pus dans la cavité buccale. De plus, le film se déforme facilement au niveau des sites d'application présentant des courbures, le film est moins irritant même lorsqu'il est fixé à un tel site d'application pendant une durée prolongée. En outre, le film de la présente invention comprend un agent de désintégration qui est dissout et libéré lorsqu'il réagit avec le sang, conduisant à la formation de microcanaux servant de voie de libération pour des médicaments, il est possible de contrôler la quantité de médicament libérée en contrôlant le nombre et la taille des microcanaux. La couche adhésive et la couche de support de la présente invention étant dissoutes et éliminées au cours du temps, un patient n'a pas à détacher manuellement de film de transport fixé dans la cavité buccale.
PCT/KR2016/012271 2015-11-25 2016-10-28 Film buccal hémostatique et de protection des plaies WO2017090902A1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP16868801.8A EP3381448A4 (fr) 2015-11-25 2016-10-28 Film buccal hémostatique et de protection des plaies
JP2017533518A JP6941839B2 (ja) 2015-11-25 2016-10-28 口腔止血及び創傷保護フィルム
US15/322,063 US10582915B2 (en) 2015-11-25 2016-10-28 Film for oral hemostasis and wound protection
CN201680004311.2A CN107106512A (zh) 2015-11-25 2016-10-28 口腔止血及伤口保护膜
CA3044944A CA3044944C (fr) 2015-11-25 2016-10-28 Film buccal hemostatique et de protection des plaies
PH12017501527A PH12017501527A1 (en) 2015-11-25 2017-08-23 Oral hemostatic and wound-protective film

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20150165396 2015-11-25
KR10-2015-0165396 2015-11-25
KR10-2016-0141695 2016-10-28
KR1020160141695A KR101901660B1 (ko) 2015-11-25 2016-10-28 구강 지혈 및 상처 보호 필름

Publications (1)

Publication Number Publication Date
WO2017090902A1 true WO2017090902A1 (fr) 2017-06-01

Family

ID=58763299

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2016/012271 WO2017090902A1 (fr) 2015-11-25 2016-10-28 Film buccal hémostatique et de protection des plaies

Country Status (1)

Country Link
WO (1) WO2017090902A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR940008675A (ko) * 1992-10-06 1994-05-16 서정욱 구재염 치료용 패취(patch)제
US6375963B1 (en) * 1999-06-16 2002-04-23 Michael A. Repka Bioadhesive hot-melt extruded film for topical and mucosal adhesion applications and drug delivery and process for preparation thereof
KR20050055858A (ko) * 2003-12-09 2005-06-14 주식회사 엘지생활건강 구강 약물 전달 시스템
KR101148470B1 (ko) * 2003-06-10 2012-05-21 데이고꾸세이약꾸가부시끼가이샤 구강점막용 펜타닐 함유 패치
KR20140110778A (ko) * 2013-03-07 2014-09-17 에스케이케미칼주식회사 고함량의 약물을 함유하는 구강 붕해 필름 및 이의 제조방법

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR940008675A (ko) * 1992-10-06 1994-05-16 서정욱 구재염 치료용 패취(patch)제
US6375963B1 (en) * 1999-06-16 2002-04-23 Michael A. Repka Bioadhesive hot-melt extruded film for topical and mucosal adhesion applications and drug delivery and process for preparation thereof
KR101148470B1 (ko) * 2003-06-10 2012-05-21 데이고꾸세이약꾸가부시끼가이샤 구강점막용 펜타닐 함유 패치
KR20050055858A (ko) * 2003-12-09 2005-06-14 주식회사 엘지생활건강 구강 약물 전달 시스템
KR20140110778A (ko) * 2013-03-07 2014-09-17 에스케이케미칼주식회사 고함량의 약물을 함유하는 구강 붕해 필름 및 이의 제조방법

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP3381448A4 *

Similar Documents

Publication Publication Date Title
JP6770157B2 (ja) 特定の投薬量の活性物質を皮膚又は粘膜に投与するための電気流体力学的に得られた繊維を含む組成物
KR101901660B1 (ko) 구강 지혈 및 상처 보호 필름
JP6929916B2 (ja) 適用部位における滞留時間が改善された、電気流体力学的に得られた繊維を含む医薬組成物
JP4619894B2 (ja) 粘膜表面への、薬剤化合物の送達に適する薬剤キャリアデバイス
US20160101061A1 (en) Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces
US20050048102A1 (en) Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces
WO2017090902A1 (fr) Film buccal hémostatique et de protection des plaies
KR20220055901A (ko) 점착성 고분자를 이용한 구강상처 보호 및 자가치료용 창상피복재
KR101771786B1 (ko) 서방성 구강 약물 전달체

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 15322063

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2017533518

Country of ref document: JP

REEP Request for entry into the european phase

Ref document number: 2016868801

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16868801

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 12017501527

Country of ref document: PH

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 3044944

Country of ref document: CA